Format

Send to

Choose Destination
Eur Thyroid J. 2018 Oct;7(5):243-250. doi: 10.1159/000490383. Epub 2018 Jul 13.

Levothyroxine/Liothyronine Combination Therapy and Quality of Life: Is It All about Weight Loss?

Author information

1
Department of Endocrinology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.
2
Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Abstract

Objectives:

According to one hypothesis, the popularity of levothyroxine (L-T4)/liothyronine (L-T3) combination therapy relates to weight loss. The purpose of this study was to detect a possible correlation between thyroid-related quality of life (QoL) and weight loss in hypothyroid patients switched from L-T4 monotherapy to L-T4/L-T3 combination therapy.

Methods:

In an open-label cohort study, all hypothyroid patients referred to the University Hospital endocrine clinic due to persistent symptoms despite adequate L-T4 monotherapy (without other explanations for the symptoms) were switched from L-T4 monotherapy to L-T4/ L-T3 combination therapy at a ratio of approximately 17/1. At baseline and after 3 months of treatment we measured: QoL by the Thyroid Patient-Reported Outcome (ThyPRO-39) questionnaire, thyroid hormones, body weight, body composition by a DEXA-scan, and cognitive function by evaluating participants' reaction time as well as working memory by the California Computerized Assessment Package (CalCAPĀ®). QoL was re-evaluated after 12 months.

Results:

Twenty-three patients participated (91% women, median age 47 years). The ThyPRO-39 composite score decreased from a median of 54 (quartiles: 34, 74) to 15 (11, 28) after 3 months (p < 0.0001), and 20 (14, 26) after 12 months, indicating a better QoL. There was no change in body weight, and no correlations between QoL and weight. There was a slight improvement in cognitive function, whereas body composition, heart rate, and serum TSH did not change.

Conclusion:

Our study on hypothyroid patients switched from L-T4 monotherapy to L-T4/L-T3 combination therapy showed a substantial improvement in QoL measured by the ThyPRO-39. This improvement could not be explained by weight loss.

KEYWORDS:

Hypothyroidism; Levothyroxine; Liothyronine; Patient-reported-outcome; Quality of Life; Weight loss

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland Icon for PubMed Central
Loading ...
Support Center